About Nautilus Biotechnology
Nautilus Biotechnology is a publicly listed company based in Seattle (United States) founded in 2016 by Sujal Patel and Parag Mallick. A proteomics platform is developed for analyzing the human proteome. Nautilus Biotechnology has raised $103.26 million across 5 funding rounds from investors including Amazon, Perceptive Advisors and Vulcan Aerospace. The company has 155 employees. Its chief executive, as recorded, is Sujal Patel. Its website nautilus.bio draws about 15 thousand monthly visits. Nautilus Biotechnology offers products and services including Proteome Analysis Platform and Targeted Proteoform Analysis. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is Nautilus Biotechnology Inc. Its competitors include Somalogic, Amunix and Elektrofi; 3 of its 3 listed competitors have raised funding.
Company details
Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, United States. A proteomics platform is being developed to analyze and quantify proteins in the human proteome, utilizing patent-protected technology. This platform supports applications in drug development and precision medicine within the biotechnology sector. Operations focus on enhancing protein quantification sensitivity for research purposes.
- Headquarters Seattle, United States
- Employees 155
- Founders Sujal Patel, Parag Mallick
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nautilus.bio
- Social LinkedIn X
- Legal Name Nautilus Biotechnology, Inc.
- Net Profit-$59 M (USD)16.64as on Dec 31, 2025
- EBITDA-$60.37 M (USD)19.64as on Dec 31, 2025
- Total Equity Funding$103.26M (USD)
in 5 rounds
- Latest Funding Round$14.7M (USD), Post-IPO
Aug 2021
- InvestorsAmazon
& 7 more
- Employee Count155
Products & Services of Nautilus Biotechnology
Nautilus Biotechnology offers a comprehensive portfolio of products and services, including Proteome Analysis Platform and Targeted Proteoform Analysis.
Platform quantifies proteins for discovery in biological research applications.
Analyzes protein variants to drive insights in drug and biomarker fields.
Funding Insights of Nautilus Biotechnology
Nautilus Biotechnology has successfully raised a total of $103.26M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $14.7 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.26M
- Total Rounds 5
- Last Round Post-IPO — $14.7M
- First Round $27.2M
(May 2018)
- Investors Count 8
All 5 funding rounds of Nautilus Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $14.7M | Post-IPO | – | – | |
| Jun 2021 | $200M | Post-IPO | – | – | – |
| Feb 2021 | $350M | Post-IPO | – | – | – |
| May 2020 | $76.06M | Series B | – | Vulcan | |
| May 2018 | $27.2M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in Nautilus Biotechnology
Nautilus Biotechnology has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Amazon, Perceptive Advisors and Vulcan Aerospace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management and philanthropic ventures linked to Bezos Expeditions. | bezosexpeditions.com | |||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage venture capital investments are made in US geographies. | defy.vc | Woodside, United States | ||
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond. | madrona.com | |||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
AME Cloud Ventures is focused on investing in data-driven technology companies. | amecloudventures.com | Palo Alto, United States | ||
Multi-category products are offered through an online marketplace. | 1994 | amazon.com | Seattle, United States | |
Develops real estate with focus on sustainability and community building. | 1986 | vulcan.com | Seattle, United States |
Investor details for Nautilus Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nautilus Biotechnology
45 people are tracked at Nautilus Biotechnology (12 in leadership, 10 in board & advisors, 23 in team); the tracked headcount is 155.
| Name | Role | Group |
|---|---|---|
Sujal Patel | Co-Founder & CEO | Leadership |
Parag Mallick | Co-Founder | Leadership |
Gwen Weld | Chief People Officer | Leadership |
Sheri Wilcox | VP, Affinity Reagent Development | Leadership |
Anna Mowry | CFO | Leadership |
Jamie Rose Kuhar | Head Of Product Management | Leadership |
Irene Sparck | Associate Director, Accounting | Leadership |
Tyler J. Ford | Head Of Content Strategy | Leadership |
Danya Cruver | Senior Director, People & Culture | Leadership |
Isaac Sprague | Associate Director, Consumables & Fluidics Engineering | Leadership |
David Groce | Head Of IT | Leadership |
Kara Juneau | Senior Director Of Assay Development, Integration, And Applications | Leadership |
Matt McIlwain | Director | Board & advisors |
Farzad Nazem | Director | Board & advisors |
Emma Lundberg | Scientific Advisor | Board & advisors |
Lee Hartwell | Scientific Advisor | Board & advisors |
Melissa Epperly | Director | Board & advisors |
Joshua LaBaer | Scientific Advisor | Board & advisors |
Matt Posard | Chair | Board & advisors |
Ruedi Aebersold | Scientific Advisor | Board & advisors |
25 more people are available in the full profile.
Complete people profiles for Nautilus Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nautilus Biotechnology
Nautilus Biotechnology is a publicly listed company on the NASDAQ with ticker symbol NAUT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jun 2021
- Listed onNASDAQ: NAUT
- Listed entityNautilus Biotechnology, Inc.
- Exchange sectorHealth technology
- ISINUS63909J1088
- Share price$2.05 (-5.53% on the day) · 2026-10-13
- Market capitalisation$260.9M
- EPS (diluted, trailing year)$-0.45
- Volume (last session)7,469,652
Financials of Nautilus Biotechnology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$59.0M | -$60.4M | |
| 2024 | -$70.8M | -$75.1M | |
| 2023 | -$63.7M | -$70.5M | |
| 2022 | -$57.9M | -$60.2M | |
| 2021 | -$50.3M | -$47.7M |
Detailed financial statements for Nautilus Biotechnology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Nautilus Biotechnology
4 dated milestones of Nautilus Biotechnology across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nautilus Biotechnology is founded.
- Funding First funding round of $27.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $14.7M.
Competitors of Nautilus Biotechnology
Nautilus Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Somalogic, Amunix and Elektrofi.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines |
Detailed competitors of Nautilus Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nautilus Biotechnology
The website of Nautilus Biotechnology (nautilus.bio) receives about 14.8K visits a month.
- Monthly visits14.8K
▲ 3.4% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nautilus Biotechnology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nautilus Biotechnology
Complete news archive for Nautilus Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nautilus Biotechnology
Nautilus Biotechnology was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Nautilus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Sujal Patel is the CEO of Nautilus Biotechnology, as recorded in our data. They have also founded this company.
Nautilus Biotechnology is a funded company, having raised a total of $103.26M across 5 funding rounds to date. The company's 1st funding round was a Series A of $27.2M, raised on May 2018.
Nautilus Biotechnology has 155 employees.
Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, United States. A proteomics platform is being developed to analyze and quantify proteins in the human proteome, utilizing patent-protected technology. This platform supports applications in drug development and precision medicine within the biotechnology sector. Operations focus on enhancing protein quantification sensitivity for research purposes.
Nautilus Biotechnology offers Proteome Analysis Platform and Targeted Proteoform Analysis.
Yes, Nautilus Biotechnology is publicly traded on NASDAQ under the ticker symbol NAUT.
Nautilus Biotechnology has 8 investors. Key investors include Amazon, Perceptive Advisors, Vulcan Aerospace, Bezos Expeditions, and defy vc.
Nautilus Biotechnology operates through Nautilus Biotechnology Inc..